Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.

Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6.

AM966是一种高亲和力、选择性、口服的LPA1拮抗剂，抑制LPA刺激的细胞内钙释放，IC50为17 nM。

Edg-2 receptor inhibitor 1 is an Edg-2 receptor inhibitor extracted from patent WO2009135590A1, Compound Example 14, has an IC50 of <0.1 μM.

AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia.

LPA2 antagonist 1 is an LPA2 antagonist with an IC50 of 17 nM.

TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (Kd high affinity of 1.7 nM and Kd low affinity of 14.5 nM)[1].

Lysophosphatidic Acid is a water-soluble endogenous phospholipid in serum acting as ligand activator for EDG-2 and EDG-4 (LPA) receptors.